IBIO vs ADMA vs HALO vs TECH vs ALNY

For growth investors, iBio, Inc.

(IBIO) is the stronger pick with 77. 8% revenue growth year-over-year, versus 5. 2% for Bio-Techne Corporation (TECH). ADMA Biologics, Inc. (ADMA) offers the better valuation at 13. 6x trailing P/E (9. 7x forward), making it the more compelling value choice. Analysts rate ADMA Biologics, Inc. (ADMA) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ADMA Biologics, Inc.

(ADMA) is the cheapest at 13. 6x versus Alnylam Pharmaceuticals, Inc. at 126. 6x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 0x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +389. 2%, compared to -99. 8% for iBio, Inc. (IBIO). Over 10 years, the gap is even starker: HALO returned +559. 7% versus IBIO's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.

(HALO) is the lower-risk stock at 0. 51β versus iBio, Inc. 's 2. 10β — meaning IBIO is approximately 310% more volatile than HALO relative to the S&P 500. On balance sheet safety, ADMA Biologics, Inc. (ADMA) carries a lower debt/equity ratio of 17% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), iBio, Inc.

(IBIO) is pulling ahead at 77. 8% versus 5. 2% for Bio-Techne Corporation (TECH). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -56. 2% for Bio-Techne Corporation. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ADMA Biologics, Inc.

(ADMA) is the more profitable company, earning 28. 8% net margin versus -45. 9% for iBio, Inc. — meaning it keeps 28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -46. 5% for IBIO. At the gross margin level — before operating expenses — IBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Halozyme Therapeutics, Inc.

(HALO) trades at 8. 0x forward P/E versus 39. 9x for Alnylam Pharmaceuticals, Inc. — 32. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 157. 0% to $21. 00.

In this comparison, TECH (0.

7% yield) pays a dividend. IBIO, ADMA, HALO, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Halozyme Therapeutics, Inc.

(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). iBio, Inc. (IBIO) carries a higher beta of 2. 10 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (HALO: +559. 7%, IBIO: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IBIO is a small-cap high-growth stock; ADMA is a small-cap high-growth stock; HALO is a small-cap high-growth stock; TECH is a small-cap quality compounder stock; ALNY is a mid-cap high-growth stock. TECH pays a dividend while IBIO, ADMA, HALO, ALNY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.